Expert Opin Drug Saf. 2012 Jan;11(1):1-5. doi: 10.1517/14740338.2012.630388. Epub 2011 Oct 20.
The ongoing progresses in the knowledge of the pathogenic mechanisms of various immune-mediated and inflammatory diseases as well as the availability of innovative biotechnological approaches have led to the development of new drugs that add to conventional treatments. Among these, tumor necrosis factor (TNF)-α inhibitors, that is, infliximab, adalimumab, etanercept, golimumab and certolizumab pegol, are now available for clinical use. This editorial discusses the recent indications of TNF-α inhibitors, the pretreatment considerations, the reported adverse events and, finally, the recommendations for its use in pregnancy.
各种免疫介导和炎症性疾病发病机制知识的不断进展，以及创新生物技术方法的出现，促使人们开发出了新的药物来辅助传统治疗。其中，肿瘤坏死因子 (TNF)-α 抑制剂，即英夫利昔单抗、阿达木单抗、依那西普、戈利木单抗和培塞利珠单抗，现已可用于临床。本文社论讨论了 TNF-α 抑制剂的最新适应证、治疗前注意事项、报告的不良事件，最后对其在妊娠期间的应用提出了建议。
